Categories: Clinical TrialNews

Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

BETHESDA, Md., Dec. 04, 2023 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company’s Chief Executive Officer, Matthias Alder, will participate in a fireside chat, hosted by FORCE Family Office, with John Vandermosten, CFA, Senior Analyst for Zacks Small-Cap Research taking place Tuesday, December 5, 2023.

Fireside Chat Details
Date: December 5, 2023
Time: 12:00 p.m. ET
Please register here to attend the live webinar.

An archived replay of the event will be available on the Company’s website here.

About Gain Therapeutics, Inc.

Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate GT-02287, in development for the treatment of GBA1 Parkinson’s disease, is currently being evaluated in a Phase 1 clinical trial.

Leveraging AI-supported structural biology, proprietary algorithms and supercomputer-powered physics-based models, the company’s SEE-Tx® discovery platform can identify novel allosteric binding sites on disease-implicated proteins, pinpointing pockets that cannot be found or drugged with current technologies. Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology. For more information, please visit GainTherapeutics.com and follow us on LinkedIn.

Investor & Media Contact:

Susan Sharpe
Linnden Communications
(919) 602-2330
susan@linndencom.com

 

Staff

Recent Posts

CloudWave Ranked #15 on Channel Partners 2025 MSP 501—The Tech Industry’s Most Prestigious List of Managed Service Providers Worldwide

MARLBOROUGH, Mass.--(BUSINESS WIRE)--CloudWave, a leading provider of integrated cybersecurity and cloud infrastructure solutions, has been…

54 minutes ago

CloudWave Ranked #15 on Channel Partners 2025 MSP 501—The Tech Industry’s Most Prestigious List of Managed Service Providers Worldwide

MARLBOROUGH, Mass.--(BUSINESS WIRE)--CloudWave, a leading provider of integrated cybersecurity and cloud infrastructure solutions, has been…

56 minutes ago

Availity Applauds Industry Commitment to Modernize Authorizations

Availity’s Intelligent Utilization Management delivers on health plans’ ambitious visionJACKSONVILLE, Fla.--(BUSINESS WIRE)--Availity, the nation’s largest…

57 minutes ago

LevelJump Announces 2025 First Quarter Results; Anticipates Revocation of Cease Trade Order

Toronto, Ontario--(Newsfile Corp. - June 23, 2025) - LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the…

1 hour ago

Agentic AI Startup VoiceCare AI Completes Successful Funding Round

Company closes $4.54M in Seed round led by Caduceus Capital Partners, with participation from Bread…

1 hour ago

TOBY Urine Test completes participation in 2025 Mayo Clinic and ASU Alliance for Health Care MedTech Accelerator

BOSTON, June 23, 2025 /PRNewswire/ -- TOBY, Inc., a biotechnology company focusing on improving early…

1 hour ago